CTRI/2024/07/071051Not yet recruitingPhase 2
ow dose Nivolumab in combination with Neoadjuvant Chemotherapy followed by concurrent Chemoradiation in advanced Carcinoma Cervix: A phase II study - NI
ICMR0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1 Histologically confirmed FIGO stage IIIC-IVa squamous, adeno or adenosquamous carcinoma of the cervix
- •2 Deemed suitable and fit for radical chemoradiation.
- •3 Medically fit to receive carboplatin and paclitaxel.
- •4 ECOG performance status 0 – 1
- •5 Aged 18 and over
Exclusion Criteria
- •1 Presence of locally advanced disease who is not fit for radical chemoradiation
- •2 Participants with more than or equal to Grade 2 peripheral neuropathy
- •3 Participants with an active, known or suspected autoimmune disease
- •4 Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of enrollment
- •5 Known history of positive test for human immunodeficiency virus or known acquired immunodeficiency syndrome
Investigators
Similar Trials
Not yet recruiting
Phase 2
Evaluation of low dose immunotherapy for lung cancerCTRI/2023/02/050126Indian Council of Medical Research
Completed
Phase 3
CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816on-Small Cell Lung CancerJPRN-jRCT2080223597Bristol-Myers Squibb K.K.642
Withdrawn
Not Applicable
A Phase II Study of Nivolumab in Combination with Radiation Therapy as Definitive Treatment for Patients with Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.KCT0004049Samsung Medical Center26
Recruiting
Phase 2
eo-adjuvant T-VEC + Nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease.skin cancerMelanomaNL-OMON49074Antoni van Leeuwenhoek Ziekenhuis24
Active, not recruiting
Phase 1
A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinomaThoracic esophageal cancerJPRN-jRCT2031180172Kato Ken36